Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34871
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 18268/20495 (89%)
造访人次 : 8740589      在线人数 : 710
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34871


    標題: Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab
    作者: Lin, Yun-Tzu
    Li, Chien-Feng
    Wu, Hung-Chang
    Jan, Yi-Hua
    Kuo, Yu-Hsuan
    貢獻者: Chi Mei Med Ctr, Dept Oncol
    Chi Mei Med Ctr, Dept Pathol
    Natl Sun Yat sen Univ, Inst Precis Med
    Chi Mei Med Ctr, Dept Med Res
    Natl Inst Canc Res, Natl Hlth Res Inst
    Chia Nan Univ, Coll Pharm & Sci
    ACT Genom Co Ltd
    Institute of Biomedical Sciences, National Sun Yat-sen University
    關鍵字: SMARCA4
    BRG1
    SWI
    SNF
    lung cancer
    non-small cell lung carcinoma
    check-point inhibitors
    nivolumab
    日期: 2023
    上傳時間: 2024-12-25 11:04:52 (UTC+8)
    出版者: FRONTIERS MEDIA SA
    摘要: SMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few. Here, we report on a 69-year-old male with heterogenous pathological presentations of SMARCA4-deficient non-small cell carcinoma. He initially presented with neck lymphadenopathies. Immunohistochemistry staining and genomic profiling confirmed the diagnosis of SMARCA4-deficient non-small cell carcinoma. The patient responded well to immune checkpoint inhibitors with nivolumab. However, new lesions with various pathological presentations and various responses to nivolumab appeared during the treatment course. The patient survived more than 3 years from the initial diagnosis. This case shows the efficacy of nivolumab to treat SMARCA4-deficient non-small cell lung carcinoma.
    關聯: Frontiers in Immunology, v.14, Article 1131448
    显示于类别:[藥學系(所)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    fimmu.2023.1131448.pdf2237KbAdobe PDF69检视/开启
    index.html0KbHTML108检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈